<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Tanaffos</journal-id><journal-id journal-id-type="iso-abbrev">Tanaffos</journal-id><journal-id journal-id-type="publisher-id">Tanaffos</journal-id><journal-title-group><journal-title>Tanaffos</journal-title></journal-title-group><issn pub-type="ppub">1735-0344</issn><issn pub-type="epub">2345-3729</issn><publisher><publisher-name>National Research Institute of Tuberculosis and Lung Disease</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25191456</article-id><article-id pub-id-type="pmc">4153247</article-id><article-id pub-id-type="publisher-id">Tanaffos-12-009</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Evaluation of Exogenous Melatonin Administration in Improvement of Sleep Quality in Patients with Chronic Obstructive Pulmonary Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Halvani</surname><given-names>Abolhasan</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Mohsenpour</surname><given-names>Fatemeh</given-names></name><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Nasiriani</surname><given-names>Khadijeh</given-names></name><xref ref-type="aff" rid="AF0002">2</xref></contrib></contrib-group><aff id="AF0001"><label>1</label>Department of Internal Medicine</aff><aff id="AF0002"><label>2</label>Nursing Department, Nursing &#x00026; Midwifery School, Shahid Sadoughi University of Medical Sciences, YAZD-IRAN</aff><author-notes><corresp id="cor1">Correspondence to: Nasiriani Kh, Address: Shaheed Sadoughi Nursing &#x00026; Midwifery School, Boali Ave. Safaeeya, Yazd, IRAN. Email address: <email xlink:href="nasiriani@gmail.com">nasiriani@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><year>2013</year></pub-date><volume>12</volume><issue>2</issue><fpage>9</fpage><lpage>15</lpage><history><date date-type="received"><day>20</day><month>2</month><year>2013</year></date><date date-type="accepted"><day>03</day><month>4</month><year>2013</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2013 National Research Institute of Tuberculosis and Lung Disease</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.</license-p></license></permissions><abstract><sec id="st1"><title>Background</title><p>COPD is primarily the disease of the lungs; nevertheless, multiple systemic manifestations including poor sleep quality and sleep disturbances have been linked to this illness. Administration of sedative hypnotics is not recommended in COPD patients, as these drugs suppress the ventilatory response and exacerbate sleep-related disorders. Melatonin is an alternative medication that has been widely used to treat sleep disturbances caused by aging and other specific conditions. We aimed to investigate the efficacy of melatonin administration in improvement of sleep quality in COPD patients.</p></sec><sec id="st2"><title>Materials and Methods</title><p>A randomized, double-blind, placebo-controlled trial was conducted. A total of 54 patients were recruited and randomly assigned into either melatonin or placebo group. Sleep quality was evaluated by Pittsburgh Sleep Quality Index (PSQI); daytime sleepiness was assessed by Epworth Sleepiness Scale (ESS). For all patients, spirometry and pulse oximetry were preformed to evaluate lung function and oxygenation.</p></sec><sec id="st3"><title>Results</title><p>Compared with placebo, melatonin administration significantly improved global PSQI score (p&#x0003c;0.001). Of PSQI individual components, sleep quality (p=0.001), sleep latency (p=0.001), sleep efficacy (p=0.003), and sleep duration (p=0.024) improved significantly. On the other hand, melatonin treatment did not significantly change indices of daytime sleepiness, lung function and oxygenation (p&#x0003e;0.05).</p></sec><sec id="st4"><title>Conclusion</title><p>Melatonin significantly improves sleep quality in COPD patients with sleep complaints. This improvement was in the absence of significant elevation in the indices of daytime sleepiness and lung function.</p></sec></abstract><kwd-group><kwd>Melatonin</kwd><kwd>Sleep quality</kwd><kwd>Chronic obstructive pulmonary disease</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="S0001"><title>INTRODUCTION</title><p>Chronic Obstructive Pulmonary Disease (COPD) is a progressive condition characterized by irreversible limitation of airflow (<xref rid="CIT0001" ref-type="bibr">1</xref>). COPD imposes a significant burden; in 2000, the World Health Organization (WHO) estimated that 2.47 million people died from COPD worldwide. It is projected that by 2020, COPD will become the third leading cause of death (<xref rid="CIT0002" ref-type="bibr">2</xref>). In the United Kingdom, COPD is the leading cause of chronic respiratory disease (<xref rid="CIT0003" ref-type="bibr">3</xref>). The main risk factor for developing COPD is smoking; others include air pollution, occupational exposure to chemical substances and dusts, poor nutritional status, alcohol consumption and alpha-1-antitrypsin deficiency (<xref rid="CIT0004" ref-type="bibr">4</xref>).</p><p>COPD primarily affects the lungs; however, various systemic complications including pulmonary hypertension (<xref rid="CIT0005" ref-type="bibr">5</xref>, <xref rid="CIT0006" ref-type="bibr">6</xref>), cor pulmonale (<xref rid="CIT0007" ref-type="bibr">7</xref>, <xref rid="CIT0008" ref-type="bibr">8</xref>), weight loss (<xref rid="CIT0009" ref-type="bibr">9</xref>, <xref rid="CIT0010" ref-type="bibr">10</xref>), insulin resistance (<xref rid="CIT0011" ref-type="bibr">11</xref>), systemic inflammation (<xref rid="CIT0012" ref-type="bibr">12</xref>), depression (<xref rid="CIT0013" ref-type="bibr">13</xref>, <xref rid="CIT0014" ref-type="bibr">14</xref>), and sleep disturbances (<xref rid="CIT0015" ref-type="bibr">15</xref>) have been linked to COPD.</p><p>An important and common systemic consequence of COPD is sleep disturbances characterized by insomnia and poor sleep quality. A rich body of subjective and objective evidence exist describing sleep disturbances in COPD patients (<xref rid="CIT0016" ref-type="bibr">16</xref>&#x02013;<xref rid="CIT0019" ref-type="bibr">19</xref>). Sleep disorders and insomnia negatively affect the quality of life of COPD patients (<xref rid="CIT0020" ref-type="bibr">20</xref>). Administration of conventional sedative-hypnotic drugs (e.g. benzodiazepines) is not recommended in patients with respiratory failure, as these drugs may suppress ventilatory response and exacerbate sleep-related breathing disorders (<xref rid="CIT0021" ref-type="bibr">21</xref>).</p><p>Melatonin, an endogenous hormone synthesized and secreted into the systemic circulation and cerebrospinal fluid by the pineal gland (<xref rid="CIT0022" ref-type="bibr">22</xref>), is believed to play a cardinal role in regulating the circadian rhythm and sleeping during the night. Melatonin has been widely used to treat sleep disturbances and insomnias caused by aging and other specific pathologic conditions (<xref rid="CIT0023" ref-type="bibr">23</xref>&#x02013;<xref rid="CIT0025" ref-type="bibr">25</xref>).</p><p>Given the principal role of melatonin in regulation of somnolence, we aimed to evaluate the efficacy of exogenous melatonin administration in improving sleep quality in COPD patients.</p></sec><sec sec-type="materials|methods" id="S0002"><title>MATERIALS AND METHODS</title><p>In order to evaluate the effect of melatonin therapy on sleep quality of COPD patients, a randomized, double-blind, placebo controlled clinical trial was conducted in Respiratory Department of Shahid Sadoughi Hospital, Yazd, Iran. All patients had a stable condition and complained of sleep disorder. The exclusion criteria were as follows: (<xref rid="CIT0001" ref-type="bibr">1</xref>) history of COPD exacerbation in the past month (<xref rid="CIT0002" ref-type="bibr">2</xref>) presence of obstructive sleep apnea (<xref rid="CIT0003" ref-type="bibr">3</xref>) history of mental disorders known to affect sleep (e.g. anxiety and depression spectrum) (<xref rid="CIT0004" ref-type="bibr">4</xref>) prior use of sedative-hypnotic drugs (<xref rid="CIT0005" ref-type="bibr">5</xref>) use of nocturnal oxygen therapy.</p><p>Fifty-four patients with confirmed diagnosis of stage II to IV COPD based on Global Initiative for Chronic Obstructive Disease (GLOD) criteria (<xref rid="CIT0026" ref-type="bibr">26</xref>) were initially recruited in this study and were randomly assigned into two groups (melatonin and placebo). Forty-eight patients completed the study protocol. For patients in melatonin group, 3 mg melatonin was prescribed one hour before bedtime and the other group received placebo.</p><p>Primary outcome was quality of night sleep evaluated by Pittsburgh Sleep Quality Index (PSQI). The PSQI is a composite score constituting of seven components: 1) subjective sleep quality 2) sleep latency 3) sleep duration 4) sleep efficacy 5) sleep disturbance 6) use of sleep medication 7) and daytime dysfunction due to inadequate night sleep. Each component has a 0-3 scale with a total score of 0-21. A total PSQI score of greater than 5 manifests poor sleep quality with a sensitivity of 89.6% and specificity of 86.5% (<xref rid="CIT0027" ref-type="bibr">27</xref>). Since patients with the history of sedative-hypnotic medication use were excluded from the study, score of the sixth component was set as zero for all patients.</p><p>Secondary outcomes were daytime sleepiness and lung function and oxygenation. Daytime sleepiness was evaluated by Epworth Sleepiness Scale (ESS), a subjective questionnaire designed to determine the level of daytime sleepiness. Patients are asked to rate the probability of sleeping or dozing on a scale of increasing probability from 0 (none) to 3 (high probability) for eight different situations (sitting and reading, watching TV, sitting inactive in a public place, being a passenger in a vehicle for an hour without a break, lying down to rest in the afternoon whenever circumstances permit, sitting and talking to someone, Sitting quietly after a lunch without alcohol, sitting in a vehicle while stopped in traffic for a few minutes). Individual scores gained from these eight sections are then summed to produce a composite score. A total score of 10 or more is considered as excessive daytime sleepiness (<xref rid="CIT0028" ref-type="bibr">28</xref>).</p><p>Lung function and oxygenation were assessed by means of spirometry and pulse oximeter (Spirolab III , MIR company, Italy ) and for each patient FEV1, FVC, FEV1/FVC, FEF 25-75 and O<sub>2</sub> saturation were calculated. After one month, evaluation of sleep quality, daytime sleepiness and lung function was repeated for all patients. Statistical analyses were performed using SPSS version 17.0 software for windows (SPSS Inc. Chicago, IL, USA). Continuous variables were expressed as mean &#x000b1; standard deviation. Categorical variables (i.e. gender and smoking status) were presented as percentage. Independent t-test was employed to compare baseline measurements of continuous variables between melatonin and placebo groups. The efficacy of treatment modality within each group was assessed using paired t-test. To compare the effects of melatonin versus placebo after one month, analysis of variance (ANOVA) was conducted. In all tests, a p-value of less than 0.05 was considered statistically significant.</p></sec><sec sec-type="results" id="S0003"><title>RESULTS</title><p>A randomized double blind, placebo-controlled trial was conducted to assess the efficacy of melatonin administration in improving sleep quality in COPD patients. Initially, a total of 54 consecutive patients with stage II to IV COPD were enrolled and randomly assigned into either melatonin or placebo group. Six patients were excluded from the study; two patients from melatonin group experienced COPD exacerbation, four patients did not return for a follow up visit (two patients from each group). At the end of trial, 48 patients completed the protocol (23 from the melatonin group and 25 from the placebo group). There were no significant side effects in the two groups.</p><p>The mean age of the study participants was 66.32 &#x000b1; 9.5 yrs. (range 46 to 83). Forty (83.3%) patients were men and 8 (16.7%) were women. Twenty-nine (60.4%) patients had a history of smoking.</p><p>Prior to treatment, there were no significant differences between the two groups in global PSQI scores, ESS scores, age, body mass index (<xref ref-type="table" rid="T0001">Table 1</xref>) and spirometry and oxygenation indices (<xref ref-type="table" rid="T0003">Table 3</xref>).
</p><table-wrap id="T0001" position="float"><label>Table 1</label><caption><p>Baseline characteristics of the melatonin and placebo groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Melatonin</th><th align="center" rowspan="1" colspan="1">Placebo</th><th align="center" rowspan="1" colspan="1">P value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Age</bold>
</td><td align="center" rowspan="1" colspan="1">65.7&#x000b1;9.34</td><td align="center" rowspan="1" colspan="1">66.85&#x000b1;9.62</td><td align="center" rowspan="1" colspan="1">0.658</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>BMI</bold>
</td><td align="center" rowspan="1" colspan="1">23.62&#x000b1;4.48</td><td align="center" rowspan="1" colspan="1">24.87&#x000b1;4.72</td><td align="center" rowspan="1" colspan="1">0.323</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>PSQI</bold>
</td><td align="center" rowspan="1" colspan="1">11.63&#x000b1;3.96</td><td align="center" rowspan="1" colspan="1">10.66&#x000b1;2.48</td><td align="center" rowspan="1" colspan="1">0.206</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>ESS</bold>
</td><td align="center" rowspan="1" colspan="1">7.04&#x000b1;4.43</td><td align="center" rowspan="1" colspan="1">6.33&#x000b1;3.5</td><td align="center" rowspan="1" colspan="1">0.530</td></tr></tbody></table><table-wrap-foot><fn><p>BMI, body mass index; PSQI, Pittsburgh Sleep Quality Index; ESS, Epworth Sleepiness Scale.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T0002" position="float"><label>Table 2</label><caption><p>PSQI (individual components and global score) before and after treatment in melatonin and placebo groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Melatonin</th><th align="center" rowspan="1" colspan="1">Placebo</th><th align="center" rowspan="1" colspan="1">P value<xref ref-type="table-fn" rid="TF0001">a</xref>
</th><th align="center" rowspan="1" colspan="1">P value<xref ref-type="table-fn" rid="TF0002">b</xref>
</th></tr></thead><tbody><tr><td align="left" rowspan="3" valign="middle" colspan="1">
<bold>Sleep quality</bold>
</td><td align="left" rowspan="1" colspan="1">Before</td><td align="center" rowspan="1" colspan="1">2&#x000b1;0.95</td><td align="center" rowspan="1" colspan="1">1.89&#x000b1;0.57</td><td align="center" rowspan="1" colspan="1">0.490</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">After</td><td align="center" rowspan="1" colspan="1">1.52&#x000b1;0.84</td><td align="center" rowspan="1" colspan="1">1.77&#x000b1;0.57</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">P value<xref ref-type="table-fn" rid="TF0003">c</xref>
</td><td align="center" rowspan="1" colspan="1">0.001</td><td align="center" rowspan="1" colspan="1">0.18</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="3" valign="middle" colspan="1">
<bold>Sleep latency</bold>
</td><td align="left" rowspan="1" colspan="1">Before</td><td align="center" rowspan="1" colspan="1">2.22&#x000b1;0.95</td><td align="center" rowspan="1" colspan="1">2.04&#x000b1;0.89</td><td align="center" rowspan="1" colspan="1">0.494</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">After</td><td align="center" rowspan="1" colspan="1">1.74&#x000b1;1.17</td><td align="center" rowspan="1" colspan="1">1.74&#x000b1;0.86</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">P value</td><td align="center" rowspan="1" colspan="1">0.001</td><td align="center" rowspan="1" colspan="1">0.23</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="3" valign="middle" colspan="1">
<bold>Sleep duration</bold>
</td><td align="left" rowspan="1" colspan="1">Before</td><td align="center" rowspan="1" colspan="1">2.48&#x000b1;0.89</td><td align="center" rowspan="1" colspan="1">2.22&#x000b1;0.69</td><td align="center" rowspan="1" colspan="1">0.056</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">After</td><td align="center" rowspan="1" colspan="1">1.70&#x000b1;1.02</td><td align="center" rowspan="1" colspan="1">2.14&#x000b1;0.76</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">P value</td><td align="center" rowspan="1" colspan="1">0.024</td><td align="center" rowspan="1" colspan="1">0.41</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="3" valign="middle" colspan="1">
<bold>Sleep efficacy</bold>
</td><td align="left" rowspan="1" colspan="1">Before</td><td align="center" rowspan="1" colspan="1">2.30&#x000b1;1.06</td><td align="center" rowspan="1" colspan="1">2.11&#x000b1;1.05</td><td align="center" rowspan="1" colspan="1">0.522</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">After</td><td align="center" rowspan="1" colspan="1">1.61&#x000b1;1.27</td><td align="center" rowspan="1" colspan="1">2.03&#x000b1;1.12</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">P value</td><td align="center" rowspan="1" colspan="1">0.003</td><td align="center" rowspan="1" colspan="1">0.15</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="3" valign="middle" colspan="1">
<bold>Sleep disturbance</bold>
</td><td align="left" rowspan="1" colspan="1">Before</td><td align="center" rowspan="1" colspan="1">1.65&#x000b1;0.83</td><td align="center" rowspan="1" colspan="1">1.74&#x000b1;0.66</td><td align="center" rowspan="1" colspan="1">0.634</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">After</td><td align="center" rowspan="1" colspan="1">1.55&#x000b1;0.65</td><td align="center" rowspan="1" colspan="1">1.7&#x000b1;0.66</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">P value</td><td align="center" rowspan="1" colspan="1">0.080</td><td align="center" rowspan="1" colspan="1">0.31</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="3" valign="middle" colspan="1">
<bold>Use of sleep medicine</bold>
</td><td align="left" rowspan="1" colspan="1">Before</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">n/a</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">After</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">P value</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="3" valign="middle" colspan="1">
<bold>Daytime dysfunction</bold>
</td><td align="left" rowspan="1" colspan="1">Before</td><td align="center" rowspan="1" colspan="1">0.91&#x000b1;0.85</td><td align="center" rowspan="1" colspan="1">0.63&#x000b1;0.84</td><td align="center" rowspan="1" colspan="1">0.178</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">After</td><td align="center" rowspan="1" colspan="1">0.78&#x000b1;0.67</td><td align="center" rowspan="1" colspan="1">0.7&#x000b1;0.91</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">P value</td><td align="center" rowspan="1" colspan="1">0.180</td><td align="center" rowspan="1" colspan="1">0.157</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="3" valign="middle" colspan="1">
<bold>Global Score</bold>
</td><td align="left" rowspan="1" colspan="1">Before</td><td align="center" rowspan="1" colspan="1">11.63&#x000b1;3.96</td><td align="center" rowspan="1" colspan="1">10.66&#x000b1;2.48</td><td align="center" rowspan="1" colspan="1">0.206</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">After</td><td align="center" rowspan="1" colspan="1">8.7&#x000b1;4.15</td><td align="center" rowspan="1" colspan="1">10.11&#x000b1;2.66</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">P value</td><td align="center" rowspan="1" colspan="1">0.002</td><td align="center" rowspan="1" colspan="1">0.065</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="TF0001"><label>a</label><p>P value calculated for comparison of baseline differences between melatonin and placebo groups</p></fn><fn id="TF0002"><label>b</label><p>P value calculated for comparison of treatment efficacy between melatonin and placebo groups</p></fn><fn id="TF0003"><label>c</label><p>P value calculated for within group comparison (before and after treatment)</p></fn><fn><p>Abbreviations: PSQI, Pittsburgh Sleep Quality Index; n/a, not applicable</p></fn></table-wrap-foot></table-wrap><table-wrap id="T0003" position="float"><label>Table 3</label><caption><p>Spirometry indices and oxygen saturation before and after treatment in melatonin and placebo groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Melatonin</th><th align="center" rowspan="1" colspan="1">Placebo</th><th align="center" rowspan="1" colspan="1">P value<xref ref-type="table-fn" rid="TF0004">a</xref>
</th><th align="center" rowspan="1" colspan="1">P value<xref ref-type="table-fn" rid="TF0005">b</xref>
</th></tr></thead><tbody><tr><td align="left" rowspan="3" valign="top" colspan="1">
<bold>FEV1/FVC</bold>
</td><td align="left" rowspan="1" colspan="1">Before</td><td align="center" rowspan="1" colspan="1">66.35 &#x000b1; 6.31</td><td align="center" rowspan="1" colspan="1">62.67 &#x000b1; 7.97</td><td align="center" rowspan="1" colspan="1">0.080</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">After</td><td align="center" rowspan="1" colspan="1">66.47 &#x000b1; 6.46</td><td align="center" rowspan="1" colspan="1">63.04 &#x000b1; 6.85</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.273</td></tr><tr><td align="left" rowspan="1" colspan="1">P value<xref ref-type="table-fn" rid="TF0006">c</xref>
</td><td align="center" rowspan="1" colspan="1">0.633</td><td align="center" rowspan="1" colspan="1">0.607</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="3" valign="top" colspan="1">
<bold>FEV1 (%)</bold>
</td><td align="left" rowspan="1" colspan="1">Before</td><td align="center" rowspan="1" colspan="1">47.04 &#x000b1; 14.68</td><td align="center" rowspan="1" colspan="1">45.26 &#x000b1; 14.81</td><td align="center" rowspan="1" colspan="1">0.672</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">After</td><td align="center" rowspan="1" colspan="1">47.52 &#x000b1; 14.83</td><td align="center" rowspan="1" colspan="1">45.54 &#x000b1; 15.17</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.729</td></tr><tr><td align="left" rowspan="1" colspan="1">P value</td><td align="center" rowspan="1" colspan="1">0.077</td><td align="center" rowspan="1" colspan="1">0.423</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="3" valign="top" colspan="1">
<bold>FVC (%)</bold>
</td><td align="left" rowspan="1" colspan="1">Before</td><td align="center" rowspan="1" colspan="1">50.35 &#x000b1; 14.01</td><td align="center" rowspan="1" colspan="1">48.74 &#x000b1; 15.18</td><td align="center" rowspan="1" colspan="1">0.701</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">After</td><td align="center" rowspan="1" colspan="1">50.30 &#x000b1; 14.43</td><td align="center" rowspan="1" colspan="1">48.92 &#x000b1; 15.49</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.841</td></tr><tr><td align="left" rowspan="1" colspan="1">P value</td><td align="center" rowspan="1" colspan="1">0.911</td><td align="center" rowspan="1" colspan="1">0.672</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="3" valign="top" colspan="1">
<bold>FEF 25-75%</bold>
</td><td align="left" rowspan="1" colspan="1">Before</td><td align="center" rowspan="1" colspan="1">38.65 &#x000b1; 17.02</td><td align="center" rowspan="1" colspan="1">35.52 &#x000b1; 16.76</td><td align="center" rowspan="1" colspan="1">0.516</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">After</td><td align="center" rowspan="1" colspan="1">38.80 &#x000b1; 16.96</td><td align="center" rowspan="1" colspan="1">36.48 &#x000b1; 16.70</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.691</td></tr><tr><td align="left" rowspan="1" colspan="1">P value</td><td align="center" rowspan="1" colspan="1">0.426</td><td align="center" rowspan="1" colspan="1">0.081</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="3" valign="top" colspan="1">
<bold>O</bold>
<sub><bold>2</bold></sub>
<bold>saturation (%)</bold>
</td><td align="left" rowspan="1" colspan="1">Before</td><td align="center" rowspan="1" colspan="1">91.52 &#x000b1; 3.61</td><td align="center" rowspan="1" colspan="1">91.00 &#x000b1; 3.44</td><td align="center" rowspan="1" colspan="1">0.607</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">After</td><td align="center" rowspan="1" colspan="1">91.91 &#x000b1; 3.89</td><td align="center" rowspan="1" colspan="1">91.26 &#x000b1; 2.82</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.423</td></tr><tr><td align="left" rowspan="1" colspan="1">P value</td><td align="center" rowspan="1" colspan="1">0.131</td><td align="center" rowspan="1" colspan="1">0.336</td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="TF0004"><label>a</label><p>P value calculated for comparison of baseline differences between melatonin and placebo groups</p></fn><fn id="TF0005"><label>b</label><p>P value calculated for comparison of treatment efficacy between melatonin and placebo groups</p></fn><fn id="TF0006"><label>c</label><p>P value calculated for within group comparison (before and after treatment)</p></fn><fn><p>FEV1, forced expiratory volume at the end of first second; FVC, forced vital capacity; FEF, forced expiratory flow</p></fn></table-wrap-foot></table-wrap><p>
<xref ref-type="table" rid="T0002">Table 2</xref> present PSQI global and sub domains score for study groups prior and after treatment. Global PSQI scores significantly improved in melatonin group after treatment (p=0.002). Comparing cases and controls, melatonin was superior to placebo in improving global PSQI score (p&#x0003c;0.001). Among PSQI individual components, sleep quality (p=0.001), sleep latency (p=0.001), sleep efficacy (p=0.003), and sleep duration (p=0.024) improved significantly in cases after melatonin administration. On the other hand, melatonin treatment did not significantly change indices of daytime sleepiness, lung function or oxygen saturation (p&#x0003e;0.05). Spirometry indices and oxygen saturation before and after treatment are presented in <xref ref-type="table" rid="T0003">Table 3</xref>.</p></sec><sec sec-type="discussion" id="S0004"><title>DISCUSSION</title><p>In this study 48 patients with stage II to IV COPD were investigated in a randomized clinical trial to reveal the effect of melatonin administration on sleep quality. Our results corroborate the results of previous studies. Shilo et al, (<xref rid="CIT0029" ref-type="bibr">29</xref>) for the first time evaluated the effects of melatonin on improvement of sleep quality in COPD patients. They studied eight patients in pulmonary ICU with exacerbation of COPD; sleep quality was assessed using wrist actinography. They observed a significant improvement in sleep quality and sleep duration after melatonin treatment. They recommended melatonin administration for sleep induction and resynchronization of biological clock in ICU patients. In contrast to Shilo et al, our study participants were in ambulatory condition and had not experienced exacerbation episodes at least in the past month. Thus, melatonin has beneficial effects on both outpatients and inpatients. Nunes et al. (<xref rid="CIT0030" ref-type="bibr">30</xref>) also used melatonin administration to resolve sleep disturbances in COPD patients. Similar to our study, PSQI was used to evaluate sleep quality. Additionally, daytime sleepiness, pulmonary function and functional exercise level were measured using ESS, spirometry and the 6-minute walk test, respectively. After melatonin prescription, global PSQI scores significantly improved compared with the placebo group. However, no significant differences were observed in other variables. Nunes et al. used melatonin in all COPD patients but we used this drug in COPD patients with sleep disturbances (PSQI &#x0003e;5). Melatonin is administered to treat poor sleep quality; therefore, selection of these patients is reasonable. Also Nunes et al. (<xref rid="CIT0030" ref-type="bibr">30</xref>) showed that melatonin had no effect on sleep latency but in our study sleep latency decreased clearly. Thus, it seems that melatonin consumption could accelerate the onset of sleep. In another study by Campos et al. (<xref rid="CIT0031" ref-type="bibr">31</xref>) effects of melatonin administration on improvement of sleep quality and pulmonary function in asthma patients were investigated. They concluded that melatonin significantly improved sleep quality but had no significant effects on peak flow and asthma symptoms. In our study melatonin had no sizeable effects on spirometry parameters such as FEV1, FVC, FEV1/FVC and FEF 25-75.</p><p>As stated earlier, melatonin has long been used for treatment of certain insomnia and regulation of circadian rhythm sleep disorders (CRSDs) (<xref rid="CIT0032" ref-type="bibr">32</xref>). For instance, Zhdanova et al. in a series of studies revealed that melatonin administration in healthy individuals reduces sleep latency and results in improved sleep efficacy (<xref rid="CIT0033" ref-type="bibr">33</xref>, <xref rid="CIT0034" ref-type="bibr">34</xref>). Melatonin levels drop with advanced age (<xref rid="CIT0035" ref-type="bibr">35</xref>, <xref rid="CIT0036" ref-type="bibr">36</xref>), and it has been hypothesized that this decrement is a principal cause for poor sleep quality and sleep disturbance in the elderly. Garfinkel et al. (<xref rid="CIT0037" ref-type="bibr">37</xref>) demonstrated that melatonin administration improves sleep efficiency in the elderly population. Moreover, a number of brain pathologies, such as Alzheimer's disease are associated with decrease in melatonin levels and resultant sleep disturbances; beneficial effects of exogenous melatonin on these patients have been proven in different studies (<xref rid="CIT0038" ref-type="bibr">38</xref>&#x02013;<xref rid="CIT0040" ref-type="bibr">40</xref>). Safety issues in melatonin administration have also been thoroughly assessed. A recent meta-analysis showed the safety of short-term administration of melatonin (<xref rid="CIT0041" ref-type="bibr">41</xref>). Our observations confirmed the previous results and no major side effects were reported in patients receiving melatonin.</p><p>Mechanisms by which melatonin exerts its main effects remain largely unknown. Recent evidence indicates that melatonin, when secreted in its physiological dose, is able to interrupt circadian rhythm that maintains insomnolence via a receptor-mediated pathway (<xref rid="CIT0022" ref-type="bibr">22</xref>).</p><p>In conclusion, wide range of therapeutic use of melatonin in treatment of sleep disturbances reveals the efficacy of this agent and the potential use of melatonin for improving sleep quality in COPD patients with sleep complaints.</p></sec></body><back><ack><title>Acknowledgment</title><p>The authors would like to thank Shahid Sadoughi University for financial support.</p></ack><ref-list><title>REFERENCES</title><ref id="CIT0001"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pauwels</surname><given-names>RA</given-names></name><name><surname>Rabe</surname><given-names>KF</given-names></name></person-group><article-title>Burden and clinical features of chronic obstructive pulmonary disease (COPD)</article-title><source>Lancet</source><year>2004</year><volume>364</volume><issue>9434</issue><fpage>613</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">15313363</pub-id></element-citation></ref><ref id="CIT0002"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>S</given-names></name></person-group><article-title>Chronic obstructive pulmonary disease</article-title><source>Current Anaesthesia &#x00026; Critical Care</source><year>2003</year><volume>14</volume><issue>2</issue><fpage>74</fpage><lpage>80</lpage></element-citation></ref><ref id="CIT0003"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raherison</surname><given-names>C</given-names></name><name><surname>Girodet</surname><given-names>PO</given-names></name></person-group><article-title>Epidemiology of COPD</article-title><source>Eur Respir Rev</source><year>2009</year><volume>18</volume><issue>114</issue><fpage>213</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">20956146</pub-id></element-citation></ref><ref id="CIT0004"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viegi</surname><given-names>G</given-names></name><name><surname>Scognamiglio</surname><given-names>A</given-names></name><name><surname>Baldacci</surname><given-names>S</given-names></name><name><surname>Pistelli</surname><given-names>F</given-names></name><name><surname>Carrozzi</surname><given-names>L</given-names></name></person-group><article-title>Epidemiology of chronic obstructive pulmonary disease (COPD)</article-title><source>Respiration</source><year>2001</year><volume>68</volume><issue>1</issue><fpage>4</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">11223724</pub-id></element-citation></ref><ref id="CIT0005"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barber&#x000e0;</surname><given-names>JA</given-names></name><name><surname>Peinado</surname><given-names>VI</given-names></name><name><surname>Santos</surname><given-names>S</given-names></name></person-group><article-title>Pulmonary hypertension in chronic obstructive pulmonary disease</article-title><source>Eur Respir J</source><year>2003</year><volume>21</volume><issue>5</issue><fpage>892</fpage><lpage>905</lpage><pub-id pub-id-type="pmid">12765440</pub-id></element-citation></ref><ref id="CIT0006"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kessler</surname><given-names>R</given-names></name><name><surname>Faller</surname><given-names>M</given-names></name><name><surname>Weitzenblum</surname><given-names>E</given-names></name><name><surname>Chaouat</surname><given-names>A</given-names></name><name><surname>Aykut</surname><given-names>A</given-names></name><name><surname>Ducolon&#x000e9;</surname><given-names>A</given-names></name><etal/></person-group><article-title>&#x0201c;Natural history&#x0201d; of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease</article-title><source>Am J Respir Crit Care Med</source><year>2001</year><volume>164</volume><issue>2</issue><fpage>219</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">11463591</pub-id></element-citation></ref><ref id="CIT0007"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vonk-Noordegraaf</surname><given-names>A</given-names></name><name><surname>Marcus</surname><given-names>JT</given-names></name><name><surname>Holverda</surname><given-names>S</given-names></name><name><surname>Roseboom</surname><given-names>B</given-names></name><name><surname>Postmus</surname><given-names>PE</given-names></name></person-group><article-title>Early changes of cardiac structure and function in COPD patients with mild hypoxemia</article-title><source>Chest</source><year>2005</year><volume>127</volume><issue>6</issue><fpage>1898</fpage><lpage>903</lpage><pub-id pub-id-type="pmid">15947300</pub-id></element-citation></ref><ref id="CIT0008"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weitzenblum</surname><given-names>E</given-names></name></person-group><article-title>Chronic cor pulmonale</article-title><source>Heart</source><year>2003</year><volume>89</volume><issue>2</issue><fpage>225</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">12527688</pub-id></element-citation></ref><ref id="CIT0009"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schols</surname><given-names>AM</given-names></name><name><surname>Slangen</surname><given-names>J</given-names></name><name><surname>Volovics</surname><given-names>L</given-names></name><name><surname>Wouters</surname><given-names>EF</given-names></name></person-group><article-title>Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>1998</year><volume>157</volume><issue>6 Pt 1</issue><fpage>1791</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">9620907</pub-id></element-citation></ref><ref id="CIT0010"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landbo</surname><given-names>C</given-names></name><name><surname>Prescott</surname><given-names>E</given-names></name><name><surname>Lange</surname><given-names>P</given-names></name><name><surname>Vestbo</surname><given-names>J</given-names></name><name><surname>Almdal</surname><given-names>TP</given-names></name></person-group><article-title>Prognostic value of nutritional status in chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>1999</year><volume>160</volume><issue>6</issue><fpage>1856</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">10588597</pub-id></element-citation></ref><ref id="CIT0011"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolton</surname><given-names>CE</given-names></name><name><surname>Evans</surname><given-names>M</given-names></name><name><surname>Ionescu</surname><given-names>AA</given-names></name><name><surname>Edwards</surname><given-names>SM</given-names></name><name><surname>Morris</surname><given-names>RH</given-names></name><name><surname>Dunseath</surname><given-names>G</given-names></name><name><surname>Luzio</surname><given-names>SD</given-names></name><etal/></person-group><article-title>Insulin resistance and inflammation - A further systemic complication of COPD</article-title><source>COPD</source><year>2007</year><volume>4</volume><issue>2</issue><fpage>121</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">17530505</pub-id></element-citation></ref><ref id="CIT0012"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gan</surname><given-names>WQ</given-names></name><name><surname>Man</surname><given-names>SF</given-names></name><name><surname>Senthilselvan</surname><given-names>A</given-names></name><name><surname>Sin</surname><given-names>DD</given-names></name></person-group><article-title>Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis</article-title><source>Thorax</source><year>2004</year><volume>59</volume><issue>7</issue><fpage>574</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">15223864</pub-id></element-citation></ref><ref id="CIT0013"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maurer</surname><given-names>J</given-names></name><name><surname>Rebbapragada</surname><given-names>V</given-names></name><name><surname>Borson</surname><given-names>S</given-names></name><name><surname>Goldstein</surname><given-names>R</given-names></name><name><surname>Kunik</surname><given-names>ME</given-names></name><name><surname>Yohannes</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Anxiety and depression in COPD: current understanding, unanswered questions, and research needs</article-title><source>Chest</source><year>2008</year><volume>134</volume><issue>4 Suppl</issue><fpage>43S</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">18842932</pub-id></element-citation></ref><ref id="CIT0014"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>I</given-names></name><name><surname>Lim</surname><given-names>Y</given-names></name><name><surname>Jung</surname><given-names>HY</given-names></name><name><surname>Park</surname><given-names>HK</given-names></name></person-group><article-title>Depression and sleep disturbance in patients with chronic obstructive pulmonary disease</article-title><source>Geriatr Nurs</source><year>2011</year><volume>32</volume><issue>6</issue><fpage>408</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">22055639</pub-id></element-citation></ref><ref id="CIT0015"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vallarino</surname><given-names>C</given-names></name><name><surname>Rajagopalan</surname><given-names>R</given-names></name><name><surname>Mini</surname><given-names>L</given-names></name></person-group><article-title>Prevalence of insomnia among patients with chronic obstructive pulmonary disease in a large database</article-title><source>Value in Health</source><year>2005</year><volume>8</volume><issue>3</issue><fpage>322</fpage></element-citation></ref><ref id="CIT0016"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leitch</surname><given-names>AG</given-names></name><name><surname>Clancy</surname><given-names>LJ</given-names></name><name><surname>Leggett</surname><given-names>RJ</given-names></name><name><surname>Tweeddale</surname><given-names>P</given-names></name><name><surname>Dawson</surname><given-names>P</given-names></name><name><surname>Evans</surname><given-names>JI</given-names></name></person-group><article-title>Arterial blood gas tensions, hydrogen ion, and electroencephalogram during sleep in patients with chronic ventilatory failure</article-title><source>Thorax</source><year>1976</year><volume>31</volume><issue>6</issue><fpage>730</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">13511</pub-id></element-citation></ref><ref id="CIT0017"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calverley</surname><given-names>PM</given-names></name><name><surname>Brezinova</surname><given-names>V</given-names></name><name><surname>Douglas</surname><given-names>NJ</given-names></name><name><surname>Catterall</surname><given-names>JR</given-names></name><name><surname>Flenley</surname><given-names>DC</given-names></name></person-group><article-title>The effect of oxygenation on sleep quality in chronic bronchitis and emphysema</article-title><source>Am Rev Respir Dis</source><year>1982</year><volume>126</volume><issue>2</issue><fpage>206</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">7103244</pub-id></element-citation></ref><ref id="CIT0018"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arand</surname><given-names>DL</given-names></name><name><surname>McGinty</surname><given-names>DJ</given-names></name><name><surname>Littner</surname><given-names>MR</given-names></name></person-group><article-title>Respiratory patterns associated with hemoglobin desaturation during sleep in chronic obstructive pulmonary disease</article-title><source>Chest</source><year>1981</year><volume>80</volume><issue>2</issue><fpage>183</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">7249764</pub-id></element-citation></ref><ref id="CIT0019"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleetham</surname><given-names>J</given-names></name><name><surname>West</surname><given-names>P</given-names></name><name><surname>Mezon</surname><given-names>B</given-names></name><name><surname>Conway</surname><given-names>W</given-names></name><name><surname>Roth</surname><given-names>T</given-names></name><name><surname>Kryger</surname><given-names>M</given-names></name></person-group><article-title>Sleep, arousals, and oxygen desaturation in chronic obstructive pulmonary disease. The effect of oxygen therapy</article-title><source>Am Rev Respir Dis</source><year>1982</year><volume>126</volume><issue>3</issue><fpage>429</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">7125332</pub-id></element-citation></ref><ref id="CIT0020"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kyle</surname><given-names>SD</given-names></name><name><surname>Morgan</surname><given-names>K</given-names></name><name><surname>Espie</surname><given-names>CA</given-names></name></person-group><article-title>Insomnia and health-related quality of life</article-title><source>Sleep Med Rev</source><year>2010</year><volume>14</volume><issue>1</issue><fpage>69</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">19962922</pub-id></element-citation></ref><ref id="CIT0021"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guilleminault</surname><given-names>C</given-names></name></person-group><article-title>Benzodiazepines, breathing, and sleep</article-title><source>Am J Med</source><year>1990</year><volume>88</volume><issue>3A</issue><fpage>25S</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">1968716</pub-id></element-citation></ref><ref id="CIT0022"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blask</surname><given-names>DE</given-names></name></person-group><article-title>Melatonin, sleep disturbance and cancer risk</article-title><source>Sleep Med Rev</source><year>2009</year><volume>13</volume><issue>4</issue><fpage>257</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">19095474</pub-id></element-citation></ref><ref id="CIT0023"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brzezinski</surname><given-names>A</given-names></name><name><surname>Vangel</surname><given-names>MG</given-names></name><name><surname>Wurtman</surname><given-names>RJ</given-names></name><name><surname>Norrie</surname><given-names>G</given-names></name><name><surname>Zhdanova</surname><given-names>I</given-names></name><name><surname>Ben-Shushan</surname><given-names>A</given-names></name><etal/></person-group><article-title>Effects of exogenous melatonin on sleep: a meta-analysis</article-title><source>Sleep Med Rev</source><year>2005</year><volume>9</volume><issue>1</issue><fpage>41</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">15649737</pub-id></element-citation></ref><ref id="CIT0024"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahlitz</surname><given-names>M</given-names></name><name><surname>Alvarez</surname><given-names>B</given-names></name><name><surname>Vignau</surname><given-names>J</given-names></name><name><surname>English</surname><given-names>J</given-names></name><name><surname>Arendt</surname><given-names>J</given-names></name><name><surname>Parkes</surname><given-names>JD</given-names></name></person-group><article-title>Delayed sleep phase syndrome response to melatonin</article-title><source>Lancet</source><year>1991</year><volume>337</volume><issue>8750</issue><fpage>1121</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">1674014</pub-id></element-citation></ref><ref id="CIT0025"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shamir</surname><given-names>E</given-names></name><name><surname>Laudon</surname><given-names>M</given-names></name><name><surname>Barak</surname><given-names>Y</given-names></name><name><surname>Anis</surname><given-names>Y</given-names></name><name><surname>Rotenberg</surname><given-names>V</given-names></name><name><surname>Elizur</surname><given-names>A</given-names></name><etal/></person-group><article-title>Melatonin improves sleep quality of patients with chronic schizophrenia</article-title><source>J Clin Psychiatry</source><year>2000</year><volume>61</volume><issue>5</issue><fpage>373</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">10847313</pub-id></element-citation></ref><ref id="CIT0026"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabe</surname><given-names>KF</given-names></name><name><surname>Hurd</surname><given-names>S</given-names></name><name><surname>Anzueto</surname><given-names>A</given-names></name><name><surname>Barnes</surname><given-names>PJ</given-names></name><name><surname>Buist</surname><given-names>SA</given-names></name><name><surname>Calverley</surname><given-names>P</given-names></name><etal/></person-group><article-title>Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary</article-title><source>Am J Respir Crit Care Med</source><year>2007</year><volume>176</volume><issue>6</issue><fpage>532</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">17507545</pub-id></element-citation></ref><ref id="CIT0027"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buysse</surname><given-names>DJ</given-names></name><name><surname>Reynolds</surname><given-names>CF</given-names><suffix>3rd</suffix></name><name><surname>Monk</surname><given-names>TH</given-names></name><name><surname>Berman</surname><given-names>SR</given-names></name><name><surname>Kupfer</surname><given-names>DJ</given-names></name></person-group><article-title>The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research</article-title><source>Psychiatry Res</source><year>1989</year><volume>28</volume><issue>2</issue><fpage>193</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">2748771</pub-id></element-citation></ref><ref id="CIT0028"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johns</surname><given-names>MW</given-names></name></person-group><article-title>A new method for measuring daytime sleepiness: the Epworth sleepiness scale</article-title><source>Sleep</source><year>1991</year><volume>14</volume><issue>6</issue><fpage>540</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">1798888</pub-id></element-citation></ref><ref id="CIT0029"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shilo</surname><given-names>L</given-names></name><name><surname>Dagan</surname><given-names>Y</given-names></name><name><surname>Smorjik</surname><given-names>Y</given-names></name><name><surname>Weinberg</surname><given-names>U</given-names></name><name><surname>Dolev</surname><given-names>S</given-names></name><name><surname>Komptel</surname><given-names>B</given-names></name><etal/></person-group><article-title>Effect of melatonin on sleep quality of COPD intensive care patients: a pilot study</article-title><source>Chronobiol Int</source><year>2000</year><volume>17</volume><issue>1</issue><fpage>71</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">10672435</pub-id></element-citation></ref><ref id="CIT0030"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nunes</surname><given-names>DM</given-names></name><name><surname>Mota</surname><given-names>RM</given-names></name><name><surname>Machado</surname><given-names>MO</given-names></name><name><surname>Pereira</surname><given-names>ED</given-names></name><name><surname>Bruin</surname><given-names>VM</given-names></name><name><surname>Bruin</surname><given-names>PF</given-names></name></person-group><article-title>Effect of melatonin administration on subjective sleep quality in chronic obstructive pulmonary disease</article-title><source>Braz J Med Biol Res</source><year>2008</year><volume>41</volume><issue>10</issue><fpage>926</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">19030713</pub-id></element-citation></ref><ref id="CIT0031"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campos</surname><given-names>FL</given-names></name><name><surname>da Silva-J&#x000fa;nior</surname><given-names>FP</given-names></name><name><surname>de Bruin</surname><given-names>VM</given-names></name><name><surname>de Bruin</surname><given-names>PF</given-names></name></person-group><article-title>Melatonin improves sleep in asthma: a randomized, double-blind, placebo-controlled study</article-title><source>Am J Respir Crit Care Med</source><year>2004</year><volume>170</volume><issue>9</issue><fpage>947</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">15306531</pub-id></element-citation></ref><ref id="CIT0032"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turek</surname><given-names>FW</given-names></name><name><surname>Gillette</surname><given-names>MU</given-names></name></person-group><article-title>Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists</article-title><source>Sleep Med</source><year>2004</year><volume>5</volume><issue>6</issue><fpage>523</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">15511698</pub-id></element-citation></ref><ref id="CIT0033"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhdanova</surname><given-names>IV</given-names></name><name><surname>Wurtman</surname><given-names>RJ</given-names></name><name><surname>Lynch</surname><given-names>HJ</given-names></name><name><surname>Ives</surname><given-names>JR</given-names></name><name><surname>Dollins</surname><given-names>AB</given-names></name><name><surname>Morabito</surname><given-names>C</given-names></name><etal/></person-group><article-title>Sleep-inducing effects of low doses of melatonin ingested in the evening</article-title><source>Clin Pharmacol Ther</source><year>1995</year><volume>57</volume><issue>5</issue><fpage>552</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">7768078</pub-id></element-citation></ref><ref id="CIT0034"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhdanova</surname><given-names>IV</given-names></name><name><surname>Wurtman</surname><given-names>RJ</given-names></name><name><surname>Morabito</surname><given-names>C</given-names></name><name><surname>Piotrovska</surname><given-names>VR</given-names></name><name><surname>Lynch</surname><given-names>HJ</given-names></name></person-group><article-title>Effects of low oral doses of melatonin, given 2-4 hours before habitual bedtime, on sleep in normal young humans</article-title><source>Sleep</source><year>1996</year><volume>19</volume><issue>5</issue><fpage>423</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">8843534</pub-id></element-citation></ref><ref id="CIT0035"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waldhauser</surname><given-names>F</given-names></name><name><surname>Weiszenbacher</surname><given-names>G</given-names></name><name><surname>Tatzer</surname><given-names>E</given-names></name><name><surname>Gisinger</surname><given-names>B</given-names></name><name><surname>Waldhauser</surname><given-names>M</given-names></name><name><surname>Schemper</surname><given-names>M</given-names></name><etal/></person-group><article-title>Alterations in nocturnal serum melatonin levels in humans with growth and aging</article-title><source>J Clin Endocrinol Metab</source><year>1988</year><volume>66</volume><issue>3</issue><fpage>648</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">3350912</pub-id></element-citation></ref><ref id="CIT0036"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>M</given-names></name><name><surname>Palacios-Bois</surname><given-names>J</given-names></name><name><surname>Schwartz</surname><given-names>G</given-names></name><name><surname>Iskandar</surname><given-names>H</given-names></name><name><surname>Thakur</surname><given-names>M</given-names></name><name><surname>Quirion</surname><given-names>R</given-names></name><etal/></person-group><article-title>Circadian rhythms of melatonin and cortisol in aging</article-title><source>Biol Psychiatry</source><year>1989</year><volume>25</volume><issue>3</issue><fpage>305</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">2914154</pub-id></element-citation></ref><ref id="CIT0037"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garfinkel</surname><given-names>D</given-names></name><name><surname>Laudon</surname><given-names>M</given-names></name><name><surname>Nof</surname><given-names>D</given-names></name><name><surname>Zisapel</surname><given-names>N</given-names></name></person-group><article-title>Improvement of sleep quality in elderly people by controlled-release melatonin</article-title><source>Lancet</source><year>1995</year><volume>346</volume><issue>8974</issue><fpage>541</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">7658780</pub-id></element-citation></ref><ref id="CIT0038"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brusco</surname><given-names>LI</given-names></name><name><surname>M&#x000e1;rquez</surname><given-names>M</given-names></name><name><surname>Cardinali</surname><given-names>DP</given-names></name></person-group><article-title>Monozygotic twins with Alzheimer's disease treated with melatonin: Case report</article-title><source>J Pineal Res</source><year>1998</year><volume>25</volume><issue>4</issue><fpage>260</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">9885996</pub-id></element-citation></ref><ref id="CIT0039"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brusco</surname><given-names>LI</given-names></name><name><surname>Fainstein</surname><given-names>I</given-names></name><name><surname>M&#x000e1;rquez</surname><given-names>M</given-names></name><name><surname>Cardinali</surname><given-names>DP</given-names></name></person-group><article-title>Effect of melatonin in selected populations of sleep-disturbed patients</article-title><source>Biol Signals Recept</source><year>1999</year><volume>8</volume><issue>1-2</issue><fpage>126</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">10085474</pub-id></element-citation></ref><ref id="CIT0040"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen-Mansfield</surname><given-names>J</given-names></name><name><surname>Garfinkel</surname><given-names>D</given-names></name><name><surname>Lipson</surname><given-names>S</given-names></name></person-group><article-title>Melatonin for treatment of sundowning in elderly persons with dementia - a preliminary study</article-title><source>Arch Gerontol Geriatr</source><year>2000</year><volume>31</volume><issue>1</issue><fpage>65</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">10989165</pub-id></element-citation></ref><ref id="CIT0041"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buscemi</surname><given-names>N</given-names></name><name><surname>Vandermeer</surname><given-names>B</given-names></name><name><surname>Hooton</surname><given-names>N</given-names></name><name><surname>Pandya</surname><given-names>R</given-names></name><name><surname>Tjosvold</surname><given-names>L</given-names></name><name><surname>Hartling</surname><given-names>L</given-names></name><etal/></person-group><article-title>Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis</article-title><source>BMJ</source><year>2006</year><volume>332</volume><issue>7538</issue><fpage>385</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">16473858</pub-id></element-citation></ref></ref-list></back></article>